Hakan Kaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hakan Kaya has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Mekin Sezik
Department of Obstetrics and Gynecology, Süleyman Demirel University Faculty of Medicine, Isparta, Turkiye
12 shared publications Okan Ozkaya
Suleyman Demirel University, Faculty of Medicine, Department of Obstetrics and Gynecology, Isparta, Turkey
11 shared publicationsHasan Sahiner
3 shared publicationsDemir Ozbasar
Suleyman Demirel University, Faculty of Medicine, Department of Obstetrics and Gynecology, Isparta, Turkey
2 shared publicationsDemir Ozbaşar
2 shared publicationsNilgun Kapucuoglu
Süleyman Demirel University
2 shared publications
Latest Publications
- 1 February 2010
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 36 (1) , 133-137
Raloxifene decreases serum malondialdehyde and nitric oxide levels in postmenopausal women with end-stage renal disease under chronic hemodialysis therapy
We prospectively aimed to investigate the relationship between raloxifene administration and serum malondialdehyde (MDA), nitric oxide (NO), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglyceride levels in postmenopausal women undergoing hemodialysis treatment for chronic renal failure. Twenty-four women scheduled for twice-weekly hemodialysis treatment were given 60 mg/day raloxifene for 3 months. Serum MDA, estimated NO, HDL, and LDL measurements were assessed initially and at month 3. We used the Mann-Whitney U and Wilcoxon signed-rank tests for comparisons. Five women discontinued the study. After controlling for baseline characteristics, mean serum MDA and estimated NO levels decreased (P = 0.0001 and P = 0.0001, respectively) from 2.01 +/- 0.40 micromol/L and 21.3 +/- 17.9 micromol/L at baseline to 1.27 +/- 0.23 micromol/L and 7.7 +/- 7.5 micromol/L at month 3, respectively. Mean serum LDL level declined (P = 0.004) from 120.0 +/- 24.3 mg/dL to 103.3 +/- 12.1 mg/dL, and mean HDL level increased (P = 0.024) from 52.2 +/- 7.8 mg/dL to 57.2 +/- 5.7 mg/dL with raloxifene administration. Oral raloxifene administration (60 mg/day) for 3 months lowered serum MDA and NO levels with favorable effects on serum lipid parameters in postmenopausal women, who were undergoing long-term hemodialysis treatment for chronic renal failure.
- 1 February 2010
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 36 (1) , 133-137
Raloxifene decreases serum malondialdehyde and nitric oxide levels in postmenopausal women with end-stage renal disease under chronic hemodialysis therapy
We prospectively aimed to investigate the relationship between raloxifene administration and serum malondialdehyde (MDA), nitric oxide (NO), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglyceride levels in postmenopausal women undergoing hemodialysis treatment for chronic renal failure. Twenty-four women scheduled for twice-weekly hemodialysis treatment were given 60 mg/day raloxifene for 3 months. Serum MDA, estimated NO, HDL, and LDL measurements were assessed initially and at month 3. We used the Mann-Whitney U and Wilcoxon signed-rank tests for comparisons. Five women discontinued the study. After controlling for baseline characteristics, mean serum MDA and estimated NO levels decreased (P = 0.0001 and P = 0.0001, respectively) from 2.01 +/- 0.40 micromol/L and 21.3 +/- 17.9 micromol/L at baseline to 1.27 +/- 0.23 micromol/L and 7.7 +/- 7.5 micromol/L at month 3, respectively. Mean serum LDL level declined (P = 0.004) from 120.0 +/- 24.3 mg/dL to 103.3 +/- 12.1 mg/dL, and mean HDL level increased (P = 0.024) from 52.2 +/- 7.8 mg/dL to 57.2 +/- 5.7 mg/dL with raloxifene administration. Oral raloxifene administration (60 mg/day) for 3 months lowered serum MDA and NO levels with favorable effects on serum lipid parameters in postmenopausal women, who were undergoing long-term hemodialysis treatment for chronic renal failure.
- 1 January 2008
- Vol. 14 (1) , CR47-51
Serum malondialdehyde, erythrocyte glutathione peroxidase, and erythrocyte superoxide dismutase levels in women with early spontaneous abortions accompanied by vaginal bleeding.
Malondialdehyde (MDA) is a marker of lipid peroxidation. Glutathione peroxidase (GPX) and superoxide dismutase (SOD) are the main enzymes responsible for the detoxification of superoxide anion. The aim was to assess whether serum MDA, erythrocyte GPX, and erythrocyte SOD levels altered during early spontaneous abortions presenting with vaginal bleeding. A group of pregnant women at less than 8 weeks' gestation with spontaneous abortion and vaginal bleeding (n=23) and a control group of healthy pregnancies with similar characteristics (n=25) were included. Serum MDA levels, erythrocyte GPX, and SOD activities were determined and compared among the groups. Characteristics, including maternal age, parity, gestational age, complete blood count values, serum total protein, serum albumin, and serum lipid profile, were similar across the groups. Spontaneous abortion prior to 8 weeks of gestation was associated with increased mean serum MDA levels and decreased mean erythrocyte SOD activity. Erythrocyte GPX values did not differ among the groups. Increased lipid peroxidation and inhibition of SOD activity might be involved in the termination of spontaneous abortions and expulsion of fetoplacental material out of the uterine cavity.
- 1 January 2008
- Vol. 14 (1) , CR47-51
Serum malondialdehyde, erythrocyte glutathione peroxidase, and erythrocyte superoxide dismutase levels in women with early spontaneous abortions accompanied by vaginal bleeding.
Malondialdehyde (MDA) is a marker of lipid peroxidation. Glutathione peroxidase (GPX) and superoxide dismutase (SOD) are the main enzymes responsible for the detoxification of superoxide anion. The aim was to assess whether serum MDA, erythrocyte GPX, and erythrocyte SOD levels altered during early spontaneous abortions presenting with vaginal bleeding. A group of pregnant women at less than 8 weeks' gestation with spontaneous abortion and vaginal bleeding (n=23) and a control group of healthy pregnancies with similar characteristics (n=25) were included. Serum MDA levels, erythrocyte GPX, and SOD activities were determined and compared among the groups. Characteristics, including maternal age, parity, gestational age, complete blood count values, serum total protein, serum albumin, and serum lipid profile, were similar across the groups. Spontaneous abortion prior to 8 weeks of gestation was associated with increased mean serum MDA levels and decreased mean erythrocyte SOD activity. Erythrocyte GPX values did not differ among the groups. Increased lipid peroxidation and inhibition of SOD activity might be involved in the termination of spontaneous abortions and expulsion of fetoplacental material out of the uterine cavity.
- 15 September 2005
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 31 (5) , 389-393
Placebo‐controlled randomized comparison of vaginal with rectal misoprostol in the prevention of postpartum hemorrhage
Aim: To compare vaginally administered misoprostol to rectally administered misoprostol and placebo in a prospective randomized placebo‐controlled study.Methods: One hundred and fifty women with singleton vaginal deliveries were randomized (50 women in each arm) to receive 400‐µg misoprostol tablets (crushed and suspended in a microenema) intravaginally, or 400‐µg misoprostol tablets rectally, or two placebo lactose tablets rectally. The medication was administered immediately after delivery of the placenta. Women with profuse hemorrhage and delayed placental separation (>30 min) were excluded. Our outcome measures were postpartum blood loss 1 h after administration, and change in hemoglobin and hematocrit values from baseline to postpartum day 1. Analysis of variance and chi‐squared tests were used to compare the outcome variables between groups.Results: One hundred and twenty‐six women were available for analysis. Baseline characteristics were similar across the groups. The number of excluded subjects, the estimated blood loss, and the drop in hemoglobin and hematocrit values did not differ between the three groups (P > 0.05).Conclusions: Misoprostol administered vaginally or rectally at a dosage of 400 µg following placental separation was not effective for decreasing postpartum bleeding in women without excessive hemorrhage.
- 15 September 2005
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 31 (5) , 389-393
Placebo‐controlled randomized comparison of vaginal with rectal misoprostol in the prevention of postpartum hemorrhage
Aim: To compare vaginally administered misoprostol to rectally administered misoprostol and placebo in a prospective randomized placebo‐controlled study.Methods: One hundred and fifty women with singleton vaginal deliveries were randomized (50 women in each arm) to receive 400‐µg misoprostol tablets (crushed and suspended in a microenema) intravaginally, or 400‐µg misoprostol tablets rectally, or two placebo lactose tablets rectally. The medication was administered immediately after delivery of the placenta. Women with profuse hemorrhage and delayed placental separation (>30 min) were excluded. Our outcome measures were postpartum blood loss 1 h after administration, and change in hemoglobin and hematocrit values from baseline to postpartum day 1. Analysis of variance and chi‐squared tests were used to compare the outcome variables between groups.Results: One hundred and twenty‐six women were available for analysis. Baseline characteristics were similar across the groups. The number of excluded subjects, the estimated blood loss, and the drop in hemoglobin and hematocrit values did not differ between the three groups (P > 0.05).Conclusions: Misoprostol administered vaginally or rectally at a dosage of 400 µg following placental separation was not effective for decreasing postpartum bleeding in women without excessive hemorrhage.
- 26 August 2005
- Published by Springer Nature in Gynecological Surgery
- Vol. 2 (4) , 307-310
Mixed germ cell tumor of the ovary mimicking unruptured ectopic pregnancy presenting with unusually high serum alpha-fetoprotein level
- 26 August 2005
- Published by Springer Nature in Gynecological Surgery
- Vol. 2 (4) , 307-310
Mixed germ cell tumor of the ovary mimicking unruptured ectopic pregnancy presenting with unusually high serum alpha-fetoprotein level
- 1 March 2005
- Vol. 50 (3) , 198-202
Does the diameter of an endometrioma predict the extent of pelvic adhesions associated with endometriosis?
To correlate ovarian endometrioma diameter with the extent of pelvic adhesions. Forty women with unilateral ovarian cysts thought to be endometriomas were prospectively recruited. The interventions were transvaginal ultrasound to measure the size of the ovarian endometrioma and a laparoscopic surgical procedure, including detailed pelvic assessment. Main outcome measures were pelvic adhesion scores using the American Fertility Society revised classification of endometriosis. Thirty-two women met the inclusion criteria. Twelve had an endometrioma < 3 cm in diameter; 12, 3-5 cm; and 8, > 5 cm. Adhesion scores from various anatomic areas did not differ across these 3 groups. No correlation between the size of the endometrioma and associated pelvic adhesions was found using multiple regression analysis. The size of an endometrioma measured by transvaginal ultrasound does not correlate with the extent of adhesive disease. Small (< 3 cm) endometriomas may be associated with a considerable degree of pelvic adhesions.
- 1 March 2005
- Vol. 50 (3) , 198-202
Does the diameter of an endometrioma predict the extent of pelvic adhesions associated with endometriosis?
To correlate ovarian endometrioma diameter with the extent of pelvic adhesions. Forty women with unilateral ovarian cysts thought to be endometriomas were prospectively recruited. The interventions were transvaginal ultrasound to measure the size of the ovarian endometrioma and a laparoscopic surgical procedure, including detailed pelvic assessment. Main outcome measures were pelvic adhesion scores using the American Fertility Society revised classification of endometriosis. Thirty-two women met the inclusion criteria. Twelve had an endometrioma < 3 cm in diameter; 12, 3-5 cm; and 8, > 5 cm. Adhesion scores from various anatomic areas did not differ across these 3 groups. No correlation between the size of the endometrioma and associated pelvic adhesions was found using multiple regression analysis. The size of an endometrioma measured by transvaginal ultrasound does not correlate with the extent of adhesive disease. Small (< 3 cm) endometriomas may be associated with a considerable degree of pelvic adhesions.
- 1 December 2004
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 30 (6) , 448-453
Relationship between the timing of hysterosalpingography before gamete intrafallopian transfer and the subsequent fertility outcome
To investigate the prognostic significance of hysterosalpingography carried out before one-sided gamete intrafallopian transfer for unexplained infertility.Fifty-nine first gamete intrafallopian transfer cycles in 59 couples with unexplained infertility were evaluated in two groups: 30 women with a hysterosalpingogram carried out 1-6 months prior to gamete intrafallopian transfer procedure combined with diagnostic laparoscopy, and 29 women with a hysterosalpingogram carried out during any other interval up to 2 years. The outcome measures were biochemical pregnancy, clinical pregnancy, miscarriage, preterm delivery, and term delivery. Groups were compared using Student's t-test and chi-squared tests. Logistic regression was used to predict the effects of hysterosalpingography on subsequent fertility outcomes.Univariate analysis yielded no significant differences across groups regarding the baseline characteristics and outcome measures. When confounding factors were controlled, carrying out hysterosalpingography at some time before 6 months of gamete intrafallopian transfer was associated with 5.2- and 3.4-fold increased clinical pregnancy and term delivery rates, respectively.An additional hysterosalpingography at most 6 months prior to gamete intrafallopian transfer procedure might improve fertility prospects. This effect could be attributed to proper selection of the fallopian tube for cannulation during transfer or some therapeutic effect of hysterosalpingography.
- 1 December 2004
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 30 (6) , 448-453
Relationship between the timing of hysterosalpingography before gamete intrafallopian transfer and the subsequent fertility outcome
To investigate the prognostic significance of hysterosalpingography carried out before one-sided gamete intrafallopian transfer for unexplained infertility.Fifty-nine first gamete intrafallopian transfer cycles in 59 couples with unexplained infertility were evaluated in two groups: 30 women with a hysterosalpingogram carried out 1-6 months prior to gamete intrafallopian transfer procedure combined with diagnostic laparoscopy, and 29 women with a hysterosalpingogram carried out during any other interval up to 2 years. The outcome measures were biochemical pregnancy, clinical pregnancy, miscarriage, preterm delivery, and term delivery. Groups were compared using Student's t-test and chi-squared tests. Logistic regression was used to predict the effects of hysterosalpingography on subsequent fertility outcomes.Univariate analysis yielded no significant differences across groups regarding the baseline characteristics and outcome measures. When confounding factors were controlled, carrying out hysterosalpingography at some time before 6 months of gamete intrafallopian transfer was associated with 5.2- and 3.4-fold increased clinical pregnancy and term delivery rates, respectively.An additional hysterosalpingography at most 6 months prior to gamete intrafallopian transfer procedure might improve fertility prospects. This effect could be attributed to proper selection of the fallopian tube for cannulation during transfer or some therapeutic effect of hysterosalpingography.
- 1 October 2004
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 36 (10) , 693-695
Lipid Peroxidation at Various Estradiol Concentrations in Human Circulation during Ovarian Stimulation with Exogenous Gonadotropins
The aim of our study was to investigate the correlation between serum malondialdehyde levels and serum estradiol concentrations in healthy human female subjects. Nine hundred and fifty-five blood samples, from infertile women undergoing controlled ovarian hyperstimulation treatment with recombinant follicle-stimulating hormone, were collected for estradiol and malondialdehyde measurements. Five groups were formed according to serum estradiol levels: Group I (< 50 pg/ml), group II (50 - 299 pg/ml), group III (300 - 999 pg/ml), group IV (1000 - 1999 pg/ml) and group V (≥ 2000 pg/ml). One-way analysis of variance was used for comparisons. Mean malondialdehyde concentrations were 1.74 ± 0.24 mmol/ml (group I), 1.53 ± 0.20 mmol/ml (group II), 1.69 ± 0.24 mmol/ml (group III), 1.77 ± 0.21 mmol/ml (group IV) and 1.86 ± 0.20 mmol/ml (group V), respectively. Mean serum malondialdehyde level at physiological estradiol concentrations (50 - 199 pg/ml, group II) was significantly (p < 0.01) lower than the mean malondialdehyde levels in other groups. Mean malondialdehyde concentrations among the remaining groups did not significantly differ. Our findings suggest that in vivo lipid peroxidation might be increased when circulating estradiol concentrations are below (< 50 pg/ml) or above (> 300 pg/ml) the physiological limits. High blood estradiol levels in human female subjects during ovarian stimulation with exogenous gonadotropins could be associated with increased serum malondialdehyde concentrations.
- 1 October 2004
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 36 (10) , 693-695
Lipid Peroxidation at Various Estradiol Concentrations in Human Circulation during Ovarian Stimulation with Exogenous Gonadotropins
The aim of our study was to investigate the correlation between serum malondialdehyde levels and serum estradiol concentrations in healthy human female subjects. Nine hundred and fifty-five blood samples, from infertile women undergoing controlled ovarian hyperstimulation treatment with recombinant follicle-stimulating hormone, were collected for estradiol and malondialdehyde measurements. Five groups were formed according to serum estradiol levels: Group I (< 50 pg/ml), group II (50 - 299 pg/ml), group III (300 - 999 pg/ml), group IV (1000 - 1999 pg/ml) and group V (≥ 2000 pg/ml). One-way analysis of variance was used for comparisons. Mean malondialdehyde concentrations were 1.74 ± 0.24 mmol/ml (group I), 1.53 ± 0.20 mmol/ml (group II), 1.69 ± 0.24 mmol/ml (group III), 1.77 ± 0.21 mmol/ml (group IV) and 1.86 ± 0.20 mmol/ml (group V), respectively. Mean serum malondialdehyde level at physiological estradiol concentrations (50 - 199 pg/ml, group II) was significantly (p < 0.01) lower than the mean malondialdehyde levels in other groups. Mean malondialdehyde concentrations among the remaining groups did not significantly differ. Our findings suggest that in vivo lipid peroxidation might be increased when circulating estradiol concentrations are below (< 50 pg/ml) or above (> 300 pg/ml) the physiological limits. High blood estradiol levels in human female subjects during ovarian stimulation with exogenous gonadotropins could be associated with increased serum malondialdehyde concentrations.
- 21 September 2004
- Published by Springer Nature in Gynecological Surgery
- Vol. 1 (4) , 241-242
Large endometrioma in an adolescent girl with Mayer-Rokitansky-Küster-Hauser syndrome
- 21 September 2004
- Published by Springer Nature in Gynecological Surgery
- Vol. 1 (4) , 241-242
Large endometrioma in an adolescent girl with Mayer-Rokitansky-Küster-Hauser syndrome
- 31 July 2004
- Published by Elsevier in Gynecologic Oncology
- Vol. 94 (1) , 229-231
Color Doppler ultrasound in ovarian fibrosarcoma
- 31 July 2004
- Published by Elsevier in Gynecologic Oncology
- Vol. 94 (1) , 229-231
Color Doppler ultrasound in ovarian fibrosarcoma